Generated July 29, 2026 at 8:32 PM ET
· Covers July 29 trading day
· 10 of 409 ready 8-Ks selected
· AI-assisted overview
The day featured several major M&A transactions: CBIZ agreed to be acquired for $55 per share, Sanara MedTech will be acquired by MiMedx for $35 per share, and Processa Pharmaceuticals completed a reverse merger with Vidya. Fortrea Holdings placed its CFO on leave following a court order. Multiple companies received Nasdaq deficiency notices, including Loop Industries, Celularity, and Foxx Development. Westlake Corp won dismissal of two antitrust lawsuits in Amsterdam. Q2 Holdings reported strong Q2 results and raised guidance, while Synergy CHC disclosed that Costco will stop carrying its FOCUSfactor products, representing 58% of revenue.
FTRE
Fortrea Holdings Inc.
leadership
negative
materiality 0.85
July 29, 2026, 6:36 AM ET
Fortrea CFO placed on leave after court order; Q2 revenue $678M, raises FY guidance
- CFO Jason Knoblauch placed on paid leave after Delaware court grants TRO in lawsuit by prior employer alleging restrictive covenant violations.
- Board member David Smith (ex-Charles River CFO) appointed Interim CFO; receives $60k/month salary and up to $900k in RSUs.
- Q2 revenue $678.2M (down 4.5% YoY); GAAP net loss $(13.2)M, adjusted EPS $0.23.
PCSA
Processa Pharmaceuticals, Inc.
M&A
negative
materiality 0.95
July 29, 2026, 7:35 AM ET
Processa completes reverse merger with Vidya, raises $200M PIPE, terminates Elion license
- Merger closed: Processa issues 558,398 common + 142,744 Series A Preferred (convertible 1:1,000) to Vidya holders.
- Raises $200M via PIPE of 163,775 Series A Preferred shares; closing expected July 30, 2026.
- Proceeds to fund operations into H2 2029 and Phase 2 studies for food allergy, CSU, and RMS.
M&A
positive
materiality 0.90
July 29, 2026, 8:12 AM ET
CBIZ to be acquired for $55.00 per share in cash; $5.2B financing committed
- Merger consideration of $55.00 per share in cash; Board unanimously approved and recommends adoption.
- Go-shop period until Aug 27, 2026; termination fee $107.5M ($49.6M if go-shop/excluded party).
- Parent termination fee $198.4M; financing commitments of $5.2B from New Mountain Partners and others.
M&A
positive
materiality 1.00
July 29, 2026, 4:21 PM ET
MiMedx to acquire Sanara MedTech for $35/share in cash and stock, ~$350M enterprise value
- Sanara shareholders to receive $33 cash plus 0.4735 MiMedx shares per share, valued at $35 total.
- Total enterprise value approximately $350 million; transaction expected to close by July 2027.
- Over $20 million in anticipated annual run-rate cost synergies post-close.
LOOP
Loop Industries, Inc.
regulatory
negative
materiality 0.75
July 29, 2026, 4:32 PM ET
Loop Industries receives Nasdaq deficiency notices for MVLS and bid price; faces potential delisting
- MVLS below $50M for 30 consecutive business days; cure period until January 20, 2027.
- Bid price below $1.00 for 30 consecutive business days; cure period until January 25, 2027.
- Company may consider applying for transfer to The Nasdaq Capital Market.
regulatory
negative
materiality 0.70
July 29, 2026, 4:15 PM ET
Celularity receives Nasdaq deficiency notice for bid price below $1.00; 180-day cure period until Jan 19, 2027
- Received Nasdaq notice on July 23, 2026, for non-compliance with minimum bid price rule (closing bid below $1.00 for 30 consecutive business days).
- Has 180 calendar days, until January 19, 2027, to regain compliance by closing bid price >= $1.00 for at least 10 consecutive business days.
- If not compliant by Jan 19, 2027, may be eligible for additional 180-day grace period if meeting other initial listing standards.
litigation
positive
materiality 0.75
July 29, 2026, 4:45 PM ET
Amsterdam court dismisses two ethylene antitrust lawsuits against Westlake; €1.025B claim rejected
- District Court of Amsterdam dismissed Shell Chemical Europe B.V. lawsuit alleging ~€1,025 million damages.
- Court also dismissed Stichting Ethylene Claims declaratory judgment action seeking unspecified damages.
- Both dismissals are subject to appeal by the plaintiffs; twelve related lawsuits remain pending at first instance.
FOXX
Foxx Development Holdings Inc.
regulatory
negative
materiality 0.65
July 29, 2026, 4:01 PM ET
Foxx Development receives Nasdaq deficiency notice for MVLS below $35M threshold
- Received Nasdaq letter on July 22, 2026 for MVLS below $35M for 30 consecutive business days.
- Compliance period ends January 19, 2027; must close at $35M+ for 10 consecutive days.
- If not compliant by deadline, Nasdaq will issue delisting notice; company may appeal.
earnings
positive
materiality 0.85
July 29, 2026, 4:19 PM ET
Q2 Holdings Q2 revenue $219.8M (+13% YoY), net income $29.9M; raises FY2026 guidance; adds $350M buyback
- Revenue $219.8M (+13% YoY); GAAP net income $29.9M vs $11.8M prior year; adjusted EBITDA $62.8M vs $45.8M.
- Subscription ARR $825.5M (+15% YoY); backlog $2.8B (+17% YoY); signed eight Enterprise/Tier 1 contracts.
- Board authorized additional $350M share repurchase; total available ~$375M; Q2 repurchased 0.5M shares at avg $45.67.
other material
negative
materiality 0.90
July 29, 2026, 4:05 PM ET
Costco to stop carrying FOCUSfactor; 58% of Synergy CHC's FY2025 revenue
- Costco informed Synergy CHC on July 15, 2026, it will discontinue FOCUSfactor products.
- Costco accounted for approximately 58% of net revenue in fiscal year ended Dec 31, 2025.
- Company expects material adverse effect on business, results, liquidity, and financial condition.